Quantification of viral inactivation by photochemical treatment with amotosalen and UV a light, using a novel polymerase chain reaction inhibition method with preamplification

被引:24
作者
Allain, Jean-Pierre
Hsu, Jocelyn
Pranmeth, Manisha
Hanson, Deborah
Stassinopoulos, Adonis
Fischetti, Lucia
Corash, Laurence
Lin, Lily
机构
[1] Cerus Corp, Concord, CA 94520 USA
[2] Univ Cambridge, Cambridge CB2 1TN, England
关键词
D O I
10.1086/509260
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. In evaluating a photochemical treatment process for inactivating parvovirus B19, there lacked simple culture methods to measure infectivity. The recently developed enzyme-linked immunospot (ELISpot) infectivity assay uses late-stage erythropoietic progenitor cells and is labor intensive and time consuming. We evaluated a novel, efficient polymerase chain reaction (PCR) inhibition assay and examined correlations with reductions in infectivity. Methods. Contaminated plasma was treated with 150 mmol/L amotosalen and 3 J/cm(2) ultraviolet A light and then tested for DNA modification using conventional PCR inhibition and a novel preamplification approach. The novel assay subjected the samples to preamplification cycles using long-template PCR, followed by quantitative PCR (QPCR) inhibition detection. Both approaches were tested for correlations with reductions in viral infectivity by comparing ELISpot assay results of identical samples. Results. The B19 preamplification inhibition assay showed detection ranges of 2-2.5 log and demonstrated quantitative correlation with up to a 5.8-log reduction in viral infectivity in ELISpot results. Conventional PCR detected a 15 log reduction in amplification, correlated with a 4.4-log reduction in viral infectivity. A range of 4-log inhibition of hepatitis B virus DNA amplification was also achieved. Conclusions. The results demonstrated that a novel preamplification QPCR assay is a useful tool for predicting reductions in infectivity after photochemical treatment. This assay was extended to show utility in circumstances where practical in vitro assays are unavailable for the determination of the efficacy of pathogen inactivation.
引用
收藏
页码:1737 / 1744
页数:8
相关论文
共 26 条
[1]   The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana [J].
Allain, JP ;
Candotti, D ;
Soldan, K ;
Sarkodie, F ;
Phelps, B ;
Giachetti, C ;
Shyamala, V ;
Yeboah, F ;
Anokwa, M ;
Owusu-Ofori, S ;
Opare-Sem, O .
BLOOD, 2003, 101 (06) :2419-2425
[2]   HUMAN PARVOVIRUS-B19 INFECTION IN HEMOPHILIACS 1ST INFUSED WITH 2 HIGH-PURITY, VIRALLY ATTENUATED FACTOR-VIII CONCENTRATES [J].
AZZI, A ;
CIAPPI, S ;
ZAKVRZEWSKA, K ;
MORFINI, M ;
MARIANI, G ;
MANNUCCI, PM .
AMERICAN JOURNAL OF HEMATOLOGY, 1992, 39 (03) :228-230
[3]   Identification and characterization of persistent human erythrovirus infection in blood donor samples [J].
Candotti, D ;
Etiz, N ;
Parsyan, A ;
Allain, JP .
JOURNAL OF VIROLOGY, 2004, 78 (22) :12169-12178
[4]   Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation [J].
Eastman, RT ;
Barrett, LK ;
Dupuis, K ;
Buckner, FS ;
Van Voorhis, WC .
TRANSFUSION, 2005, 45 (09) :1459-1463
[5]   Human parvovirus B19 [J].
Heegaard, ED ;
Brown, KE .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (03) :485-+
[6]   Efforts in minimizing risk of viral transmission through viral inactivation [J].
Horowitz, B ;
Ben-Hur, E .
ANNALS OF MEDICINE, 2000, 32 (07) :475-484
[7]   In vitro photochemical inactivation of cell-associated human T-cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen [J].
Jauvin, V ;
Alfonso, RD ;
Guillemain, B ;
Dupuis, K ;
Fleury, HJA .
TRANSFUSION, 2005, 45 (07) :1151-1159
[8]  
Kerr S, 1999, J MED VIROL, V57, P179, DOI 10.1002/(SICI)1096-9071(199902)57:2&lt
[9]  
179::AID-JMV16&gt
[10]  
3.0.CO